ENSAIOS CLÍNICOS 2021

INVESTIGADOR PRINCIPAL	TÍTULO	FASE	EUDRACT	PROMOTOR
AMILOIDOSE | UNIDADE CORINO DE ANDRADE				
Teresa Coelho	A Multicenter, Open-Label, Extension Study to Evaluate the Long-term Safety and Efficacy of Patisiran in Patients With Familial Amyloidotic Polyneuropathy Who Have Completed a Prior Patisiran Clinical Study	III	2014-003877-40	Alnylam Pharmaceuticals, Inc.
Teresa Coelho	An Open-label Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of Patisiran-LNP in Patients With Hereditary Transthyretin-mediated Amyloidosis (hATTR Amyloidosis) With Disease Progression Post-Orthotopic Liver Transplant	III	2018-003519-24	Alnylam Pharmaceuticals, Inc.
Teresa Coelho	HELIOS-A: A Phase 3 Global, Randomized, Open-label Study to Evaluate the Efficacy and Safety of ALN-TTRSC02 in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)	III	2018-002098-23	Alnylam Pharmaceuticals, Inc.
Teresa Coelho	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of AG10 in Subjects With Symptomatic Transthyretin Amyloid Cardiomyopathy	III	2018-004280-32	Eidos Therapeutics, Inc.

Teresa Coelho	A phase 3, randomized, double-blind, placebo controlled multicenter study to evaluate the efficacy and safety of patisiran in patients with transthyretin mediated amyloidosis with cardiomyopathy	III	2019-001458-24	Alnylam Pharmaceuticals, Inc.
Teresa Coelho	A Phase 3 Global, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of ION-682884 in Patients with Hereditary Transthyretin-Mediated Amyloid Polyneuropathy	III	2019-001698-10	Ionis Pharmaceuticals
Teresa Coelho	A phase 3, randomized, double-blind, placebo controlled, multicenter study to evaluate the eficacy and safety of vitrusiran in patients with transthyretin amyloidosis with cardiomyopathy (ATTR amyloidosis with cardiomyopathy)	II	2019-003153-28	Alnylam Pharmaceuticals, Inc.
CARDIOLOGIA				
André Luz	A Phase 3 Global, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ION-682884 in Patients With Transthyretin-Mediated Amyloid Cardiomyopathy	III	2019-002835-27	Ionis Pharmaceuticals

CUIDADOS INTENSIVOS				
Filipe Nery	Effects of Plasma Exchange With Human Serum Albumin 5% (PE-A 5%) on Short-term Survival in Subjects With "Acute-On-Chronic Liver Failure" (ACLF) at High Risk of Hospital Mortality	III	2016-001787-10	Grifols
Miguel Tavares	A Phase IIb/III Operationally Seamless, Open-label, Randomised, Sequential, Parallel-group Adaptive Study to Evaluate the Efficacy and Safety of Daily Intravenous Alteplase Treatment Given up to 5 Days on Top of Standard of Care (SOC) Compared With SOC Alone, in Patients With Acute Respiratory Distress Syndrome (ARDS) Triggered by COVID-19	III	2020-002913-16	Boehringer Ingelheim
CUIDADOS INTENSIVOS NEONATAIS E PEDIÁTRICOS				
Elisa Proença	A Phase 2b, Multicenter, Randomized, Open-label, Controlled, 3-Arm Study to Evaluate the Clinical Efficacy and Safety of SHP607 in Preventing Chronic Lung Disease Through 12 Months Corrected Age Compared to Standard Neonatal Care in Extremely Premature Infants	II	2018-001393-16	Shire Inc
Elisa Proença	Prophylactic treatment of the ductus arteriosus in preterm infants by acetaminophen	III	2019-004297-26 †	INSERM

Liliana Pinho	Effect of ALlopurinol in addition to hypothermia for hypoxic-ischemic Brain Injury on Neurocognitive Outcome	III	2016-000222-19 †	University Hospital Tuebingen
DERMATOLOGIA				
Inês Lobo	A Randomized, Double-blind, Multi-center Study Assessing Short (16 Weeks) and Long-term Efficacy (up to 1 Year), Safety, and Tolerability of 2 Subcutaneous Secukinumab Dose Regimens in Adult Patients With Moderate to Severe Hidradenitis Suppurativa	III	2018-002063-26	Novartis
Inês Lobo	A Multicenter, double-blind, randomized withdrawal extension study of subcutaneous secukinumab to demonstrate long-term efficacy, safety and tolerability in subjects with moderate to severe hidradenitis suppurative	III	2019-003230-17	Novartis
Inês Lobo	A randomized, double blind, placebo-controlled, multi-center, parallel group study to evaluate the efficacy and safety of dupilumab in patients with prurigo nodularis who are inadequately controlled on topical prescription therapies or when those therapies are not advisable	III	2019-003801-90	Sanofi
Tiago Torres	A Multicenter, Open Label Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis	III	2016-003046-87	Abbvie

Tiago Torres	A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects With Moderate to Severe Atopic Dermatitis	III	2018-001383-28	Abbvie
ENDOCRINOLOGIA				
Helena Cardoso	A 26-week Trial Comparing the Effect and Safety of Once Weekly Insulin Icodec and Once Daily Insulin Degludec, Both With or Without Non-insulin Anti-diabetic Drugs, in Subjects With Type 2 Diabetes Treated With Basal Insulin	III	2020-000454-10	NovoNordisk
Isabel Palma	A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke	III	2018-004565-14	Amgen
Rui Carvalho	A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Event-driven Phase 3 Study to Investigate Efficacy and Safety of Finerenone on the Reduction of Cardiovascular Morbidity and Mortality in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease in Addition to Standard of Care	III	2015-000950-39	Bayer

GASTRENTEROLOGIA				
Daniela Ferreira	A Phase 2/3, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Crohn's Disease	II	2017-002195-13	Janssen
Paula Lago	Study of Treat to Target Versus Routine Care Maintenance Strategies in Crohn's Disease Patients Treated With Ustekinumab	III	2016-002918-43	Janssen
Paula Lago	A Phase 2b/3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis	II	2018-004002-25	Janssen
GINECOLOGIA				
Hélder Ferreira	An International Phase 3 Open-Label, Single-Arm, Safety and Efficacy Extension Study to Evaluate Relugolix Co-Administered With Low-Dose Estradiol and Norethindrone Acetate in Women With Endometriosis-Associated Pain	III	2017-004066-10	Myovant Sciences GmbH
HEMATOLOGIA				

Cristina Gonçalves	A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide, Bortezomib and Low-Dose Dexamethasone Versus Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma	III	2014-000268-17	Celgene
Eugénia Cruz	A Phase 3, Open-label, Randomized, Multi-center, Controlled Trial to Evaluate the Pharmacokinetics and Pharmacodynamics of Edoxaban and to Compare the Efficacy and Safety of Edoxaban With Standard of Care Anticoagulant Therapy in Pediatric Subjects From Birth to Less Than 18 Years of Age With Confirmed Venous Thromboembolism (VTE)	III	2016-000991-49	Daiichi-Sankyo
Jorge Coutinho	A Prospective, Randomized, Open Label, Two Arm Phase III Study to Evaluate Treatment Free Remission (TFR) Rate in Patients With Philadelphia-positive CML After Two Different Durations of Consolidation Treatment With Nilotinib 300mg BID	III	2012-005124-15	Novartis
Jorge Coutinho	A Phase 3, Double-Blind, Placebo-controlled Study of Quizartinib Administered in Combination With Induction and Consolidation Chemotherapy, and Administered as Continuation Therapy in Subjects 18 to 75 Years Old With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia	III	2015-004856-24	Daiichi-Sankyo
Jorge Coutinho	A Phase 2/3, Randomised, Multicentre Study of MOR208 With Bendamustine Versus Rituximab With Bendamustine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) Who Are Not Eligible for High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT)	II	2014-004689-11	Morphosis

Luísa Regadas	A Phase III, Randomized, Double-blind, Controlled Multicenter Study of Intravenous PI3K Inhibitor Copanlisib in Combination With Standard Immunochemotherapy Versus Standard Immunochemotherapy in Patients With Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)	III	2015-001088-38	Bayer
Rita Coutinho	A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With Rituximab Versus Placebo in Combination With Rituximab in Treatment Naïve Subjects With Follicular Lymphoma	III	2016-003202-14	Pharmacyclics
Rita Coutinho	A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) Plus Rituximab Versus Bendamustine Plus Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation	III	2019-000413-36	BeiGene
INFECIOLOGIA				
Ana Horta	A Phase 3, Randomized, 2-Part Clinical Study in HIV-1-Infected Heavily Treatment Experienced Participants Evaluating the Antiretroviral Activity of Blinded MK-8591 and Doravirine Each Compared to Placebo (Part 1) and the Antiretroviral Activity, Safety, and Tolerability of Open-Label MK-8591A (Part 2)	III	2019-000588-26	Merck Sharp & Dohme
André Santos Silva	A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Remdesivir in Participants With Severely Reduced Kidney Function Who Are Hospitalized for COVID-19	III	2020-005416-22	Gilead

Josefina Mendez	A phase IIb, randomized, controlled, dose-ranging study of oral GCK3640254 in combination with nucleoside reverse transcriptase inhibitors for induction of HIV-1 virologic suppression followed by na evaluation of maintenance of virologic suppression when oral GSK3640254 is combined with oral dolutegravir in HIV-1 infected, antiretroviral therapy-naive adults	II	2019-004435-23	ViiV
Josefina Mendez	A Phase IIb, Randomized, Double-blind, Parallel-group Study to Assess the Efficacy, Safety, Tolerability, and Resistance Profile of GSK3640254 in Combination With Dolutegravir Compared to Dolutegravir Plus Lamivudine in HIV-1 Infected, Treatment-naïve Adults	II	2021-000016-28	Glaxo Smith Kline
Rui Sarmento e Castro	A Phase III, Randomised, Double Blind, Multicentre, Parallel Group, Non Inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in Human Immunodeficiency Virus 1 Infected Treatment naïve Adults	III	2015-004418-95	Glaxo Smith Kline
Rui Sarmento e Castro	An Open-Label, Multicenter Study to Evaluate Long-Term Outcomes With ABT-450/Ritonavir/ ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection	III	2014-001022-14	Abbvie
MEDICINA				
Fabienne Gonçalves	An open label, multicentre study to evaluate pharmacokinetics, safety and efficacy of zamicastat as adjunctive therapy in pulmonary arterial hypertension (PAH)	II	2018-002448-10	Bial

Fabienne Gonçalves	A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Group-sequential, Adaptive, Phase 3 Study With Open-label Extension Period to Assess the Efficacy and Safety of Selexipag as an add-on to Standard of Care Therapy in Subjects With Inoperable or Persistent/Recurrent After Surgical and/or Interventional Treatment Chronic Thromboembolic Pulmonary Hypertension	III	2018-002823-41	Janssen
Irene Marques	A Multicenter, Randomized, Parallel Group, Double Blind, Active and Placebo Controlled Study of BAY1753011, a Dual V1a/V2 Vasopressin Receptor Antagonist, in Patients With Congestive Heart Failure	II	2018-004059-18	Bayer
Irene Marques	A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy ans safety of finerenone on morbidiry and mortality in participants with heart failure (NIHA II-IV) and LVEF ≥ 40%	III	2020-000306-29	Bayer
João Neves	A Double-blind, Placebo-controlled, Multi-centre, Clinical Trial to Investigate the Efficacy and Safety of 12 Months of Therapy With Inhaled Colistimethate Sodium in the Treatment of Subjects With Non-cystic Fibrosis Bronchiectasis Chronically Infected With Pseudomonas Aeruginosa	III	2015-2743-33	Zanbom
NEFROLOGIA				
Sofia Santos	A Phase 3b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of TRC101 in Delaying Chronic Kidney Disease Progression in Subjects With Metabolic Acidosis	III	2018-001303-36	TRICIDA

NEUROLOGIA				
Alexandre Mendes	A Phase III, Double-Blind, Randomized, Placebo-Controlled and Parallel-Group Study to Evaluate the Efficacy and Safety of Opicapone, as Add-on to Stable Levodopa (L-DOPA) Plus a Dopa Decarboxylase Inhibitor (DDCI) Therapy in Early Idiopathic Parkinson's Disease Patients, With an Open-Label Extension	III	2020-005011-52	Bial
Ana Martins Silva	A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Variable Treatment Duration Study Evaluating the Efficacy and Safety of Siponimod (BAF312) in Patients With Secondary Progressive Multiple Sclerosis Followed by Extended Treatment With Open-label BAF312	III	2012-003056-36	Novartis
Ana Martins Silva	A Randomized, Double-blind, Double-dummy, Parallel-group Study Comparing the Efficacy and Safety of Ofatumumab Versus Teriflunomide in Patients With Relapsing Multiple Sclerosis	III	2015-005419-33	Novartis
Ana Martins Silva	Open-label, Randomized, 2-arm, Active Comparator Study to Evaluate Safety and Tolerability in Portuguese Patients With Relapsing Remitting Multiple Sclerosis (MS) Transitioning From Current Subcutaneous Interferon Therapy to Peginterferon Beta 1a (PLEGRIDY™)	IV	2016-000434-21	Biogen
Ana Martins Silva	An Open-Label, Single-Arm Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Early Stage Relapsing Remitting Multiple Sclerosis	III	2016-002937-31	Roche

Ana Martins Silva	Multicenter, Non-comparative Extension to Study AC-058B301, to Investigate the Long-term Safety, Tolerability, and Control of Disease of Ponesimod 20 mg in Subjects With Relapsing Multiple Sclerosis	III	2016-004719-10	Actelion
Ana Martins Silva	A 2-Year Prospective Study to Assess Health-related Quality of Life In Subjects With Highly-Active Relapsing Multiple Sclerosis Treated With Mavenclad®	II	2017-002632-17	Merck
Ana Martins Silva	An Open-label, Single Arm, Multi-center Extension Study Evaluating Long-term Safety, Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis	III	2017-004703-51	Novartis
Ana Martins Silva	A Phase IIIb, randomized, double-blind, placebocontrolled, parallel-group, multicenter study to evaluate efficacy of upper limb function and safety of ocrelizumab	III	2018-001511-73	Roche
Ana Martins Silva	A single-arm, prospective, multicenter, open-label study to evaluate ofatumumab treatment effectiveness and patient-reported outcomes in patients with relapsing multiple sclerosis transitioning from dimethyl fumarate or fingolimod therapy to ofatumumab	III	2019-001341-40	Novartis

Ana Martins Silva	A Phase IIIB Multicenter, Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis	III	2020-000894-26	Roche
Ana Martins Silva	A Phase III Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Ocrelizumab In Adult Patients With Primary Progressive Multiple Sclerosis	III	2019-003919-53	Roche
Ana Martins Silva	A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis	III	NCT04458051	Sanofi
Ana Martins Silva	A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis	III	2020-000647-30	Sanofi
Ana Martins Silva	A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio®) in Participants With Relapsing Forms of Multiple Sclerosis	III	2020-000644-55	Sanofi

Ana Martins Silva	A Phase III Multicenter Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Adult Patients With Relapsing Multiple Sclerosis	III	2019-004857-10	Roche
Ana Martins Silva	A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared With Teriflunomide, in Participants With Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety	III	2019-004980-36	Merck Healthcare KGaA
Ana Martins Silva	Single Arm, Open Label Multicentre Extension Study To Evaluate The Effectiveness And Safety Of Ocrelizumab In Patients With Multiple Sclerosis Previously Enrolled In A F. Hoffmann-La Roche Sponsored Ocrelizumab Phase IIIb/IV Clinical Trials	III	2017-004886-29	Roche
Carlos Andrade	A 12-month Prospective, Randomized, Interventional, Global, Multi-center, Activecontrolled Study Comparing Sustained Benefit of Two Treatment Paradigms (Erenumab qm vs. Oral Prophylactics) in Adult Episodic Migraine Patients	IV	2018-001228-20	Novartis
Ernestina Santos	A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement-Inhibitor-Naïve Adult Patients With Generalized Myasthenia Gravis	III	2018-003243-39	Alexion

Luís Maia	A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study of Gantenerumab in Patients With Early (Prodromal to Mild) Alzheimer's Disease	III	2017-001365-24	Roche
Luís Maia	An Open-Label, Multicenter, Rollover Study to Evaluate the Safety, Tolerability, and Efficacy of Long-Term Gantenerumab Administration in Participants With Alzheimer's Disease	III	2020-000766-42	Roche
Luís Maia	A Randomised Double-blind Placebo-controlled Clinical Trial Investigating the Effect and Safety of Oral Semaglutide in Subjects With Early Alzheimer´s Disease	III	2020-004848-29	NovoNordisk
Luís Maia	Randomised Double-blind Placebo-controlled Clinical Trial Investigating the Effect and Safety of Oral Semaglutide in Subjects With Early Alzheimer´s Disease	III	2020-004864-25	NovoNordisk
OFTALMOLOGIA				
Bernardete Pessoa	A Two-year, Three-arm, Randomized, Double-masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Adult Patients With Visual Impairment Due to Diabetic Macular Edema	III	2017-004742-23	Novartis

Miguel Lume	A 64-week, Two-arm, Randomized, Double-masked, Multicenter, Phase IIIb Study Assessing the Efficacy and Safety of Brolucizumab 6 mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen in Patients With Neovascular Agerelated Macular Degeneration	III	2019-000716-28	Novartis
Miguel Lume	A 56-week Phase IIIb/IV, Open-label, One-arm Extension Study to Assess the Efficacy and Safety of Brolucizumab 6 mg in a Treat-to-Control Regimen With Maximum Treatment Intervals up to 20 Weeks for the Treatment of Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2303	III	2020-002349-40	Novartis
Miguel Lume	A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion	III	2020-000440-63	Roche
Miguel Lume	Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration	III	2019-003851-12	Bayer
ONCOLOGIA				
António Araújo	A Randomized, Phase 3 Trial With Anti-PD-1 Monoclonal Antibody Pembrolizumab (MK-3475) Versus Placebo for Patients With Early Stage NSCLC After Resection and Completion of Standard Adjuvant Therapy	III	2015-000575-27	Merck Sharp & Dohme

António Araújo	A Phase III, Open-label, Multicenter Trial of Avelumab (MSB0010718C) Versus Platinum-based Doublet as a First-line Treatment of Recurrent or Stage IV PD-L1+ Non-small Cell Lung Cancer	III	2015-001537-24	MERCK
António Araújo	A Phase III Study of BBI-608 Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma	III	2016-004359-57 †	Boston Biomedical
António Araújo	A Randomized, Open-Label (Formerly Double-Blind), Phase 2 Trial to Assess Safety and Efficacy of Lenvatinib at Two Different Starting Doses (18 mg vs. 14 mg QD) in Combination With Everolimus (5 mg QD) in Renal Cell Carcinoma Following One Prior VEGF-Targeted Treatment	II	2016-002778-11	Eisai
António Araújo	A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Subjects With Extensive Stage Small Cell Lung Cancer	III	2016-003503-64	Abbvie
António Araújo	A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma	III	2018-000519-26	Astellas

António Araújo	Randomized, Open Label Phase 3 study of SAR408701 versus Docetaxel in Previously Treated Non Squamous Non-Small Cell Lung Cancer patients with CEACAM5 positive tumors	III	2019-001273-81	Sanofi
António Araújo	A Randomized Phase 3 Multicenter Open-Label Study to Compare the Efficacy of TAK-788 Versus Platinum-Based Chemotherapy as First-Line Treatment in Patients With NSCLC With EGFR Exon 20 Insertion Mutations	III	2019-001845-42	Millennium Pharmaceuticals
António Araújo	Phase III, randomized, open-label, controlled study to evaluate the efficacy, safety and pharmacokinetics of atezolizumab in combination with cabozantinib compared with docetaxel monotherapy in patients with metastatic non-small cell lung cancer previously treated with an immune checkpoint inhibitor and platinum-based chemotherapy	III	2020-000100-011	Roche
António Araújo	A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer	III	2020-000743-31	Janssen
António Araújo	A Phase 2 Study of Futibatinib in Patients With Specific FGFR Aberrations	II	2019-004084-49	Taiho Oncology, Inc

António Araújo	A Phase 2 Basket Study of the Oral TRK Inhibitor Larotrectinib in Subjects With NTRK Fusion-positive Tumors	II	2015-003582-28	Bayer
António Araújo	A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Patients With EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer	III	2020-000633-40	Janssen
Fernando Gonçalves	Phase 2 Study of MCLA-128-based Combinations in Metastatic Breast Cancer (MBC): MCLA-128/ Trastuzumab/Chemotherapy in HER2-positive MBC and MCLA-128/Endocrine Therapy in Estrogen Receptor Positive and Low HER2 Expression MBC	II	2017-002821-39	Merus
Fernando Gonçalves	A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer	III	2016-004362-26	Lilly
Fernando Gonçalves	Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive (Human Epidermal Receptor) Breast Cancer: FDG-PET Response-adapted Strategy	II	2016-002676-27 †	MedSIR

Fernando Gonçalves	Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-label, Active-controlled, Multicenter Trial	III	2018-002990-24	Radius Pharmaceuticals, Inc.
Fernando Gonçalves	A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of GDC 0077 plus palbociclib and fulvestrant versus placebo plus palbociclib and fulvestrant in patients with locally advanced or metastatic pik3ca-mutant hormone receptor-positive, her2 negative breast cancer	III	2019-002455-42	Roche
Fernando Gonçalves	A phase III, randomised, double-blind, placebo-controlled, multicentre study of the efficacy and safety of atezolizumab plus chemotherapy for patients with early relapsing recurrent (inoperable locally advanced or metastatic) triple-negative breast cancer	III	2016-005119-42	Roche
Joana Febra	A Phase III Randomized Trial of MK-3475 (Pembrolizumab) Versus Standard Treatment in Subjects With Recurrent or Metastatic Head and Neck Cancer	III	2014-001749-26	Merck Sharp & Dohme
Joana Febra	A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects With Metastatic Prostate Cancer	III	2017-003364-12	Janssen

Joana Febra	A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of Talazoparib With Enzalutamide In Metastatic Castration-resistant Prostate Cancer	III	2017-003295-31	Pfizer
Joana Febra	A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) with Pembrolizumab (MK-3475) in Combination with Transarterial Chemoembolization (TACE) Versus TACE in Participants with Incurable/Non-metastatic Hepatocellular Carcinoma (LEAP-012)	III	2019-002345-37	Merck Sharp & Dohme
Joana Febra	A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects with Metastatic Castration-Resistant Prostate Cancer	III	2020-000348-77	Exelixis, Inc.
Joana Febra	A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib Versus Gemcitabine With Cisplatin in Subjects With Advanced/Metastatic or Inoperable Cholangiocarcinoma With FGFR2 Gene Fusions/ Translocations	III	2018-004004-19	QED Therapeutics, Inc.
Joana Febra	A Phase 3, Randomized, Open-label Study to Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Gemcitabine and Cisplatin in Cisplatin-eligible Participants With Muscle-invasive Bladder Cancer	III	2020-003106-31	Merck Sharp & Dohme

Joana Simões	A Randomized, Double-Blind, Phase III Study of Pembrolizumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (KEYNOTE-756)	III	2017-003507-22	Merck Sharp & Dohme
Joana Simões	A Phase II study of Adjuvant PALbociclib as an Alternative to CHemotherapy in Elderly patientS with high-risk ER+/HER2- early breast cancer	II	2018-002553-30	Grupo Solti
Joana Simões	A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib/+Paclitaxel vs Placebo+Paclitaxel as First-line Treatment for Patients With Locally Advanced (Inoperable) or Metastatic TNBC	III	2018-004687-64	Astra Zeneca
Joana Simões	A Phase 2 Study of TAS-120 in Metastatic Breast Cancers Harboring Fibroblast Growth Factor Receptor (FGFR) Amplifications	II	2019-001164-30	Taiho Oncology, Inc
Joana Simões	A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the Treatment of Chemotherapy-Candidate Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Locally Recurrent Inoperable or Metastatic Breast Cancer	III	2020-005407-38	Merck Sharp & Dohme

Noémia Afonso	An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease	III	2016-003467-19	Novartis
Noémia Afonso	A Phase II, Open Label, Randomised, Multi-centre Study to Assess the Safety and Efficacy of Agents Targeting DNA Damage Repair in Combination with Olaparib versus Olaparib Monotherapy in the Treatment of Metastatic Triple Negative Breast Cancer Patients Stratified by Alterations in Homologous Recombinant Repair (HRR)-related Genes (including BRCA1/2)	II	2017-002361-22	Astra Zeneca
Noémia Afonso	A Multi-centre, Double-blind, Placebo-controlled, Randomised Phase II Trial to Compare Efficacy of Xentuzumab in Combination With Everolimus and Exemestane Versus Everolimus and Exemestane in Women With HR+ / HER2- Metastatic Breast Cancer and Non-visceral Disease	II	2017-003131-11	Boehringer Ingelheim
Noémia Afonso	A Phase 3, Multicenter, Randomized, Open-label, Active Controlled Trial of DS-8201a, an Anti-HER2-antibody Drug Conjugate (ADC), Versus Treatment of Physician's Choice for HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects	III	2018-003069-33	Daiichi-Sankyo
Paula Fidalgo	A Phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy-induced Thrombocytopenia in Patients Receiving Chemotherapy for Treatment of Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer	III	2018-001006-28	Amgen

Paula Fidalgo	A Phase 3 Multicenter, Randomized, Open Label, Active-controlled, Study of AMG 510 Versus Docetaxel for the Treatment of previously treated Locally Advanced and unresectable or Metastatic NSCLC Subjects with Mutated KRAS p.G12C	III	2019-003582-18	Amgen
Paula Fidalgo	A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation	II	2018-001400-11	Amgen
Sérgio Azevedo	A phase III, randomized, double-blind, placebo-controlled study of atezolizumab with or without tiragolumab (anti-TIGIT antibody) in patients with locally advanced esophageal squamous cell carcinoma	III	2020-001178-31	Roche
Sílvia Lopes	Phase III Randomized Sequential Open-label Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal Cancer	III	2018-000347-60 †	Grupo de Tratamiento de los Tumores Digestivos (TTD)
Sílvia Lopes	A Phase 3 Randomized Placebo-controlled Double blind Study of Romiplostim for the Treatment of Chemotherapy-induced Thrombocytopenia in Patients Receiving FOLFOX-based Chemotherapy for Treatment of Gastrointestinal or Colorectal Cancer	III	2017-002992-25	Amgen

Sílvia Lopes	A Phase 3 Randomized, Double-blind, Multicenter, Global Study of Monalizumab or Placebo in Combination With Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With an Immune Checkpoint Inhibitor	III	2019-004770-25	Astra Zeneca
ORTOPEDIA				
Adélio Vilaça	A Randomized, Open-Label, Study Drug-Dose Blind, Multicenter Study to Evaluate the Efficacy and Safety of JNJ-70033093 (BMS-986177), an Oral Factor XIa Inhibitor, Versus Subcutaneous Enoxaparin in Subjects Undergoing Elective Total Knee Replacement Surgery	II	2018-004237-32	Janssen
PEDIATRIA				
Caldas Afonso	Phase 3, Single-arm, Open-label, Multidose, Titration, Pharmacokinetic, Pharmacodynamic, and Safety Study of Etelcalcetide in Children and Adolescents 2 to < 18 Years of age With Secondary Hyperparathyroidism and Chronic Kidney Disease Receiving Maintenance Hemodialysis	III	2018-004608-21	Amgen
Catarina Prior	A Phase 4, Multicenter, 2-part Study Composed of a 1-Year Randomized, Double-blind, Parallel-group, Placebo-controlled, Active-comparator, Dose-optimization Evaluation Followed by a 1-Year Open-label Evaluation to Assess the Safety and Efficacy of Guanfacine Hydrochloride Prolonged-release (SPD503) in Children and Adolescents Aged 6 to 17 Years With Attention-deficit/Hyperactivity Disorder	IV	2018-000821-29	Takeda

Emília Costa	A Phase II, Open-label, Non-controlled, Intra-patient Dose-escalation Study to Characterize the Pharmacokinetics After Oral Administration of Eltrombopag in Pediatric Patients With Refractory, Relapsed or Treatment Naive Severe Aplastic Anemia or Recurrent Aplastic Anemia	II	2015-003166-91	Novartis
Helena Mansilha	Effect and Safety of Liraglutide 3.0 mg on Weight Management in Children With Obesity Aged 6 to Below 12 Years: 56-week, Double-blind, Randomised, Placebo-controlled Trial	III	2020-000546-34	NovoNordisk
Laura Marques	A Two-arm, Phase 2/3 Multicentre, Open-label, Randomised Study Evaluating Safety and Antiviral Effect of Current Standard Antiretroviral Therapy Compared to Once Daily Integrase Inhibitor Administered With Darunavir/ Ritonavir (DRV/r) in HIV-1 Infected, Virologically Suppressed Paediatric Participants	III	2013-001476-37 †	Pediatric European Network for Treatment of AIDS
Laura Marques	An open-label, multi-centre, randomised (1:1), non-inferiority, Phase II/III, 96-week, 2-arm clinical trial to compare the efficacy and toxicity of DTG plus 2 NRTI vs. standard of care (SOC) in HIV-infected children aged less than 18 years who are starting first-line ART (ODYSSEY A) or switching to second-line ART (ODYSSEY B)	III	2014-002632-14 †	Pediatric European Network for Treatment of AIDS
Manuel Magalhães	A double blind, randomised, placebo-controlled trial to evaluate the dose-exposure and safety of nintedanib per os for 24 weeks, followed by open label treatment with nintedanib of variable duration, in children and adolescents (6 to 17 year-old) with clinically significant fibrosing Interstitial Lung Disease	III	2018-004530-14	Boehringer Ingelheim

Sónia Figueiroa	An Open-Label, Randomized, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 in Pediatric Subjects Aged 10 to Less Than 18 Years for the Treatment of Relapsing-Remitting Multiple Sclerosis, With Optional Open-Label Extension	III	2018-003008-38	Biogen
PNEUMOLOGIA				
Joana Gomes	A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation	III	2018-001954-91	Sanofi
UNIDADE DE IMUNOLOGIA CLÍNICA				
Ana Campar	A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab	III	2011-005667-25	Human Genome Sciences
António Marinho	A Phase 3, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Rheumatoid Arthritis	III	2012-003686-17	Lilly
António Marinho	Study of Safety and Efficacy of Multiple VAY736 Doses in Patients With Moderate to Severe Primary Sjogren's Syndrome (pSS)	II	2016-003292-22	Novartis

António Marinho	A phase IIb, double-blind, randomized, placebo-controlled, multicenter, dose-ranging study to evaluate the efficacy and safety profile of PF-06700841 in participants with active systemic lupus erythematosus (SLE)	II	2018-004175-12	Pfizer
António Marinho	A Phase III randomized, double-blind, placebo controlled parallel-group, multicenter study of subcutaneous secukinumab 300mg added onto Standard of Care to demonstrate the efficacy at 52 weeks and to assess the long term efficacy, safety and tolerability up to 2 years in patients with Active ISN/RPS class III or IV Lupus Nephritis	III	2019-003211-57	Novartis
António Marinho	A Phase 2 Dose Ranging Study to Evaluate the Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE) With Inadequate Response to Standard of Care (SOC) Therapy	II	2019-000328-16	Amgen
UROLOGIA				
Miguel Ramos	A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men with Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)	III	2018-003135-30	Urovant
Miguel Ramos	A randomized, placebo-controlled, double-blind, parallel-group, multi-center, proof-of-concept study to assess the efficacy and safety of BAY 1817080 in patients with overactive bladder (OAB) over a 12-week treatment period	II	2019-002575-34	Bayer

Frederico Teves	A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, With an Observational Follow-up of PSMA-PET-Negative Patients	III	2019-002957-46	Janssen

Legenda: † Ensaios da iniciativa do investigador